Market Cap: $505.47B
Market Cap: $505.47B

AbbVie: Navigating the Post-Humira Landscape AbbVie Inc. ( ABBV ) is strategically evolving as it transitions away from its once-flagship drug, Humira. With the expiration of Humira's patent, the comp…

The Legacy of Humira and Its Decline Humira has played a pivotal role in AbbVie's success, generating billions in revenue from its efficacy in treating autoimmune diseases. However, with the looming p…

AbbVie Inc. ( ABBV ) is navigating a pivotal transformation in the biopharmaceutical landscape, emerging from the shadows of its once-flagship product, Humira. As the patent expired on Humira, which h…

AbbVie Inc. ( ABBV ) is experiencing a remarkable transformation as it adapts to market shifts following the patent expiration of its flagship drug, Humira. Initially, Humira's unparalleled success es…

AbbVie Inc. ( ABBV ) is undergoing a significant transformation as it seeks to redefine its identity within the biopharmaceutical sector following the expiration of patent protections for its flagship…

AbbVie Inc. ABBV is currently navigating a transformative phase, pivoting from its reliance on the blockbuster drug Humira towards a more diversified product portfolio and innovative therapies. This s…

AbbVie Inc. ( ABBV ) is on a transformative path, reshaping its business model amid changing market dynamics and the expiration of its flagship drug, Humira. The biopharmaceutical giant faces challeng…

AbbVie Inc. ( ABBV ) is navigating a transformative phase within the biopharmaceutical landscape, marked by strategic acquisitions and innovative product offerings. This journey aims to solidify AbbVi…

AbbVie Inc. ( ABBV ) is undergoing a transformative phase as it seeks to solidify its position within the biopharmaceutical landscape. Following the successful trajectory of its flagship product Humir…

AbbVie Inc. ( ABBV ) is making significant strides in the biopharmaceutical landscape through strategic acquisitions and product innovations. These initiatives are generating investor interest and set…

AbbVie Inc. ABBV is rapidly redefining its place within the biopharmaceutical sector, mainly through strategic acquisitions aimed at enhancing its therapeutic offerings. One vital step in this transfo…

AbbVie Inc. ( ABBV ) is solidifying its presence in the biopharmaceutical industry through strategic acquisitions and innovative drug developments aimed mainly at treating immune-mediated conditions.…

AbbVie Inc. ( ABBV ) has been making significant strides in the biopharmaceutical landscape, particularly through strategic acquisitions and regulatory successes that bolster its offerings in immunolo…

AbbVie Inc. ( ABBV ) is making significant strides in the biopharmaceutical industry, primarily through strategic acquisitions and expanding its portfolio of immunotherapy products. The company has be…

AbbVie Inc. ( ABBV ) is rapidly emerging as a leader in the biopharmaceutical industry through strategic innovations and advancements in the immunology space. The company is enhancing its market prese…

AbbVie Inc. ABBV is currently redefining its position in the pharmaceutical industry through a series of strategic advancements that promise to bolster its growth trajectory. The company has been maki…

AbbVie Inc. ( ABBV ) is making significant strides in various therapeutic areas, particularly through its dermatological treatments and recent approvals that promise to reshape its market outlook. The…

AbbVie (Ticker: ABBV) is poised for a significant breakthrough in dermatological treatments following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products fo…

AbbVie (Ticker: ABBV) has made significant strides in expanding its pediatric healthcare offerings with the recent approval of its drug Skyrizi for children and adolescents suffering from moderate to…

AbbVie (Ticker: ABBV) solidifies its position in the immunology space with its recent announcement regarding a major acquisition of Apogee Therapeutics for approximately $10.9 billion. The deal includ…

Allergan Aesthetics, a subsidiary of AbbVie (Ticker: ABBV), is making significant strides in the aesthetic market following the recent approval of SKINVIVE by JUVÉDERM by the U.S. FDA. This innovative…

AbbVie (Ticker: ABBV) continues to demonstrate its commitment to advancing cancer treatment with the recent presentation of the Phase 3 CLL14 trial data at the European Hematology Association (EHA) 20…

AbbVie Inc (Ticker: ABBV) is poised to present vital new results from its blood cancer treatment portfolio at the upcoming European Hematology Association (EHA) Congress in 2026. The company plans to…

AbbVie (Ticker: ABBV) makes a significant stride in oncology with its ovarian cancer drug Elahere gaining approval from the NHS in England for treating advanced, platinum-resistant ovarian cancer. Thi…

AbbVie (Ticker: ABBV) secures a pivotal regulatory victory with the recent approval of AQUIPTA (atogepant) by the European Commission for acute migraine treatment in adults. This significant achieveme…

AbbVie (Ticker: ABBV) announces an important expansion in its treatment options for patients diagnosed with chronic lymphocytic leukemia (CLL). The European Commission has authorized an updated label…

AbbVie is making significant strides in expanding access to its drug SKYRIZI for patients suffering from ulcerative colitis in Canada. This expansion is facilitated through new formulary listings and…

AbbVie (NYSE: ABBV) has announced a major milestone in its manufacturing strategy, revealing a $1.4 billion investment to build a new pharmaceutical manufacturing campus in Durham, North Carolina. Thi…
Innovating Aesthetic Solutions: Allergan Aesthetics Unveils New Products at AAD Meeting Allergan Aesthetics, a subsidiary of AbbVie, captures industry attention with the presentation of four influenti…
Undetectable Aesthetics: Allergan Aesthetics Drives a New Trend in Cosmetic Enhancements At the recent Aesthetic & Anti-Aging Medicine World Congress (AMWC) held in Monaco, Allergan Aesthetics, a nota…
AbbVie Takes Significant Steps to Combat Cancer Through Major League Baseball Partnership AbbVie announces a landmark partnership with Major League Baseball (MLB) that underscores its commitment to ca…
### Shifting Paradigms in Aesthetic Medicine: AbbVie’s Allergan Aesthetics Sets New Standards Allergan Aesthetics, a subsidiary of AbbVie, reveals significant findings from new global research that in…
### New Treatments Ignite Competition in Psoriasis Care The recent FDA approval of Icotyde, an innovative oral interleukin-23 (IL-23) receptor antagonist developed by Protagonist Therapeutics in colla…
Competitive Pressures in the Obesity Drug Market: Implications for AbbVie The competitive landscape in the obesity drug market significantly shapes the future for companies like AbbVie as it navigates…
AbbVie Faces Increasing Competition in the Psoriasis Treatment Market In the ever-evolving landscape of psoriasis treatments, AbbVie faces formidable new competition as Johnson & Johnson (J&J) announc…
Innovative Power Solutions: A Game-Changer for Data Centers in Europe's Energy Landscape A new development in Dublin marks a significant turning point in energy management for data centers in Europe.…
### AbbVie Innovates Amid Market Shifts AbbVie Inc. continues to solidify its position in the pharmaceutical landscape despite facing recent stock price declines. The company is particularly focused o…
AbbVie’s Strategic Innovations Lead the Charge in Healthcare Resilience In a world where economic fluctuations often disrupt various sectors, AbbVie stands resilient within the healthcare industry, pa…
Shifting Patient Priorities in Aesthetic Medicine: The Rise of Medical Weight Loss Treatments Recent data from Allergan Aesthetics, a division of AbbVie, highlights a notable transformation in patient…
AbbVie's Breakthrough in Crohn's Disease Treatment: Phase 3 AFFIRM Study Results Announced AbbVie Inc. recently reports promising topline results from its Phase 3 AFFIRM study, which evaluates the eff…
Enveric Biosciences Strengthens Patent Portfolio Amid Legal Challenges Enveric Biosciences Inc. faces a turning point in its innovation journey as it announces the withdrawal of a Post-Grant Review (P…
AbbVie's Commitment to Innovative Manufacturing for Neuroscience and Obesity Therapies AbbVie announces a significant investment of $380 million to construct two state-of-the-art active pharmaceutical…
AbbVie wins FDA clearance for first all‑oral, fixed‑duration frontline CLL regimen AbbVie announces that the U.S. Food and Drug Administration approves a supplemental new drug application for the all‑…
AbbVie declares quarterly payout as part of long-term capital plan Dividend Policy Anchors Capital Allocation Strategy AbbVie announces a quarterly cash dividend of $1.73 per share, payable May 15, 20…
AbbVie’s strategic pivot to serotonergic agonists as a pipeline refresh AbbVie is positioning itself to capitalize on a rapid industry shift toward novel serotonergic agonists (NSAs) as a way to refre…
New serotonergic class reshapes AbbVie’s CNS strategy AbbVie is among a group of large pharmaceutical companies repositioning their central nervous system (CNS) portfolios around novel serotonergic ag…
AbbVie's Strategic Crossroads: AI Shift Alters Health-Care Landscape AI's ripple effects on drug discovery, regulation and deal-making Pharmaceutical companies such as AbbVie face a rapid recalibratio…
AbbVie's Allergan unit opens platform for breast implant patient stories IRVINE, Calif., Feb 3, 2026 — Allergan Aesthetics, an AbbVie company, is launching a nationwide Faces of Natrelle® Testimonial…
Irvine, Calif., Feb. 3, 2026 — Allergan Aesthetics, an AbbVie company, announces the nationwide launch of the Faces of Natrelle® Testimonial Program, inviting eligible breast augmentation and reconstr…
AbbVie Expands Manufacturing Footprint with Strategic Acquisition in Arizona AbbVie Inc., a leading biopharmaceutical company, announces a definitive agreement to acquire a device manufacturing facili…